A 12-month, double-blind, randomised, placebo-controlled clinical trial to determine the efficacy of multiple-dose testosterone undecanoate administration on neuropsychological, psychosocial and biological markers (biomarkers) in male participants with traumatic brain injury.

Trial Profile

A 12-month, double-blind, randomised, placebo-controlled clinical trial to determine the efficacy of multiple-dose testosterone undecanoate administration on neuropsychological, psychosocial and biological markers (biomarkers) in male participants with traumatic brain injury.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Testosterone undecanoate (Primary)
  • Indications Alzheimer's disease; Craniocerebral trauma
  • Focus Pharmacodynamics
  • Acronyms HIT
  • Most Recent Events

    • 03 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ANZCTR record.
    • 10 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top